3861715
Last Update Posted: 2020-10-08
Recruiting status is unknown
Females accepted | 20 Years-34 Years |
180 Estimated Participants | No Expanded Access |
Observational Study | Accepts healthy volunteers |
Single Follicular Dexarelix for LH Suppression During Ovarian Stimulation in Oocyte Donors.
A randomized prospective study in the evaluation of the long acting GnRH antagonist Degarelix against the classical multidose regime with Ganirelix for LH suppression during the follicular phase of an ovarian stimulation cycle in oocyte donors.
A randomized prospective study of the use of single dose of the long acting GnRH antagonist Degarelix for ovarian stimulation cycle in oocyte donors: Ovarian stimulation started on cycle Day2 with gonadotropins 175-300 IU and either GnRH antagonist single dose Degarelix or multidose GnRH antagonist Ganirelix initiated on Day6 of the stimulation cycle. Agonist triggering was used in both groups for oocyte maturation. Blastocyst formation rate and Live Birth Rates were estimated for both groups.
Eligibility
Relevant conditions:
Infertility
Premature Ovarian Failure
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Evaggelos Papanikolaou, MD,PhD
drvagpapanikolaou@yahoo.gr
00302310424294
Data sourced from ClinicalTrials.gov